#GLP-1
Total 8 articles
Semaglutide's patent expired in China on March 20. Now at least 10 Chinese rivals are queuing for approval, some claiming better efficacy. A $14B market is up for grabs.
GLP-1 drugs like Ozempic are showing unexpected potential to treat multiple addictions simultaneously, from smoking to opioids, in what could be medicine's biggest breakthrough.
As GLP-1 medications surge in popularity for weight loss, users report an unexpected side effect that's not quite depression - a troubling emotional numbness that's raising questions about the true cost of pharmaceutical weight management.
PRISM by Liabooks
Place your ad in this space
[email protected]
Oprah Winfrey reflects on her 'horrible' 1985 Tonight Show interview with Joan Rivers and discusses her 20-year struggle with body-shaming and the impact of GLP-1 medication.
The China obesity drug price war 2026 is heating up as companies slash prices by 80%. Discover how Novo Nordisk and Eli Lilly are responding to local competition.
Explore the controversial rise of AlloClae cadaver fat filler. As GLP-1 drugs make natural fat transfers difficult, this $10,000 donor-derived filler is changing the cosmetic industry.
Amanda Bynes shares her 28lb weight loss journey in 2025. From 180 to 152 lbs using Semaglutide (GLP-1), Bynes is embracing transparency and recovery.
PRISM by Liabooks
Place your ad in this space
[email protected]
Discover how the approval of new weight-loss drugs is forcing food giants like Nestlé to overhaul their products. An analysis of the 'Ozempic effect' on consumer habits and the investment landscape.
